About Eledon
Eledon is a company based in Irvine (United States) founded in 2004. Eledon has raised $1.89 million across 7 funding rounds from investors including Orbimed and BVF Partners. The company has 31 employees as of December 31, 2024. Eledon has completed 1 acquisition, including Anelixis Therapeutics. Eledon offers products and services including Tegoprubart. Eledon operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, CareDx, Neurocrine and ADMA Biologics, among others.
- Headquarter Irvine, United States
- Employees 31 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Eledon Pharmaceuticals, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$36.18 M (USD)68.95as on Dec 31, 2024
-
EBITDA
-$70.22 M (USD)-64.73as on Dec 31, 2024
-
Total Equity Funding
$1.89 M (USD)
in 7 rounds
-
Latest Funding Round
$50 M (USD), Post-IPO
May 09, 2024
-
Investors
Orbimed
& 1 more
-
Employee Count
31
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Eledon
Eledon is a publicly listed company on the NASDAQ with ticker symbol ELDN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Eledon
Eledon offers a comprehensive portfolio of products and services, including Tegoprubart.
Antibody designed to prevent immune rejection in organ transplants.
People of Eledon
Unlock access to complete
Unlock access to complete
Funding Insights of Eledon
Eledon has successfully raised a total of $1.89M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Eledon
Eledon has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Orbimed and BVF Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US private equity investments are managed by BVF Partners.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked |
Investor details for Eledon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eledon
Eledon has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Anelixis Therapeutics.
Investment portfolio details for Eledon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
CD40 and SOD1 targeting drugs are developed for ALS treatment.
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for Eledon
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Eledon
Detailed financials for Eledon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eledon Comparisons
Peer comparison for Eledon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Eledon
Eledon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, CareDx, Neurocrine and ADMA Biologics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Medical solutions for transplant patients are developed and provided.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
Detailed competitors of Eledon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eledon
Complete news archive for Eledon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eledon
Eledon was founded in 2004 and raised its 1st funding round 7 years after it was founded.
Eledon is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Eledon is a funded company, having raised a total of $1.89M across 7 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Eledon is 31.
Eledon was founded in 2004 and is based in Irvine, United States. Operations focus on the biotechnology sector, where solutions for organ and cellular transplantation are provided to address autoimmune and neurodegenerative diseases. The CD40L pathway is targeted through antibodies, with AT-1501 developed for pro-inflammatory responses in autoimmune conditions, transplant rejection, and neuroinflammation. AT-2001 is also advanced for autoimmune indications.
Eledon's top competitors include Jazz Pharmaceuticals, CareDx and ADMA Biologics.
Eledon offers Tegoprubart.
Yes, Eledon is publicly traded on NASDAQ under the ticker symbol ELDN.
Eledon has made 1 acquisition, including Anelixis Therapeutics.
Eledon has 2 investors. Key investors include Orbimed, and BVF Partners.
The ticker symbol of Eledon is ELDN on NASDAQ.